Literature DB >> 15607803

The cell biology of the human natural killer cell CD94/NKG2A inhibitory receptor.

Francisco Borrego1, Madhan Masilamani, Juraj Kabat, Tolib B Sanni, John E Coligan.   

Abstract

To avoid destruction of normal bystander cells, natural killer (NK) cells must provide a continuous supply of functional inhibitory receptors to their cell surface. After interaction with its ligand HLA-E, which is expressed on normal cells, the C-type lectin inhibitory receptor CD94/NKG2A suppresses activation signaling processes. CD94/NKG2A receptors continuously recycle from the cell surface through endosomal compartments and back again in a process that requires energy and the cytoskeleton. This steady state process appears to be largely unaffected by exposure to ligand. CD94/NKG2A receptors move freely within the plasma membrane and accumulate at the site of contact with the ligand bearing target cells (or monoclonal antibodies (mAb) coated beads). As expected, ligated CD94/NKG2A receptors are less mobile than the nonligated receptors, and the lipid raft marker cholera toxin B is excluded from the CD94/NKG2A enriched target cell contact sites. Also, methylcyclodextrin does not interfere with CD94/NKG2A accumulation at these contact sites. The constant renewal of CD94/NKG2A receptors at the cell surface and their free mobility within the plasma membrane likely facilitates and insures inhibitory capacity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15607803     DOI: 10.1016/j.molimm.2004.07.031

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  30 in total

1.  NKG2A and CD56 are coexpressed on activated TH2 but not TH1 lymphocytes.

Authors:  Robert J Freishtat; Lindsay W Mitchell; Svetlana D Ghimbovschi; Samuel B Meyers; Eric P Hoffman
Journal:  Hum Immunol       Date:  2006-03-27       Impact factor: 2.850

2.  NK cell survival mediated through the regulatory synapse with human DCs requires IL-15Ralpha.

Authors:  Fabienne Brilot; Till Strowig; Susanne M Roberts; Frida Arrey; Christian Münz
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

3.  Different natural killer (NK) receptor expression and immunoglobulin E (IgE) regulation by NK1 and NK2 cells.

Authors:  E Aktas; M Akdis; S Bilgic; R Disch; C S Falk; K Blaser; C Akdis; G Deniz
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

Review 4.  Primate-specific regulation of natural killer cells.

Authors:  Peter Parham; Laurent Abi-Rached; Lilit Matevosyan; Achim K Moesta; Paul J Norman; Anastazia M Older Aguilar; Lisbeth A Guethlein
Journal:  J Med Primatol       Date:  2010-08       Impact factor: 0.667

5.  NK cell terminal differentiation: correlated stepwise decrease of NKG2A and acquisition of KIRs.

Authors:  Vivien Béziat; Benjamin Descours; Christophe Parizot; Patrice Debré; Vincent Vieillard
Journal:  PLoS One       Date:  2010-08-06       Impact factor: 3.240

Review 6.  Endocytosis and intracellular trafficking of human natural killer cell receptors.

Authors:  Madhan Masilamani; Giovanna Peruzzi; Francisco Borrego; John E Coligan
Journal:  Traffic       Date:  2009-08-05       Impact factor: 6.215

Review 7.  Immunopathogenesis and therapeutic approaches in pediatric celiac disease.

Authors:  Shreya Agarwal; Oormila Kovilam; Terence L Zach; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2016-04-01       Impact factor: 4.473

Review 8.  Endocytosis as a mechanism of regulating natural killer cell function: unique endocytic and trafficking pathway for CD94/NKG2A.

Authors:  Giovanna Peruzzi; Madhan Masilamani; Francisco Borrego; John E Coligan
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

Review 9.  Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering.

Authors:  May Daher; Katayoun Rezvani
Journal:  Curr Opin Immunol       Date:  2018-03-30       Impact factor: 7.486

10.  Natural killer cells in obesity: impaired function and increased susceptibility to the effects of cigarette smoke.

Authors:  Donal O'Shea; Tom J Cawood; Cliona O'Farrelly; Lydia Lynch
Journal:  PLoS One       Date:  2010-01-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.